Scientists raised $9 million today to fund clinical trials for a technology that illuminates cancer cells during surgery.
These scientists launched a database of genetic information to help researchers understand the root causes of breast and ovarian cancer.
Editor’s Pick HopeLab’s six free-to-play online minigames help kids understand why they need to take medicine that makes them feel sick.
Syros Pharmaceuticals integrates gene control research and drug discovery with disease biology and genomic data. Its initial focus is on cancer, but the platform will be applicable to other areas in the future.
Bina’s platform significantly reduces the time and cost of processing the human genome, which has far-reaching implications for the world of healthcare.
Editor’s Pick Ayasdi is working with the nation’s top hospitals and medical researchers to uncover more targeted treatments for disease.
Molecular information company Foundation Medicine raises $42.5M to improve cancer treatment
You’re as likely to get cancer from using your cell phone as from drinking coffee. Say what? That’s right, cell phone radiation is not dangerous.
Cell phone radiation might be carcinogenic — meaning the radiation could be linked to some cases of cancer — according to a panel assembled by the World Health Organization (WHO) to study the effects of the devices.
A former Facebook president’s pet project for philanthropy, Causes, is coming into its own, announcing today it has closed a $9 million round of mezzanine funding.
(UPDATED: See below.)
Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital.
(UPDATE: The merger is dead.)
Yet another biotech has succumbed to Big Pharma’s deep-pocketed blandishments. Agensys, a decade-old Santa Monica, Calif., biotech with an early-stage pipeline, just agreed to sell itself to Japan’s Astellas Pharma for $387 million in cash. The company’s shareholders can receive up to another $150 million in milestone payments.
(UPDATED: See below.)
Featured companies: Antisense Pharma, Arteriocyte, Excelimmune, Fluxion Biosciences
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical
Featured companies: AngioScore, Forsight Labs, Genoptix, Metastatix, Optherion, QLT
Featured companies: Aveo Pharmaceuticals, Aviir, deltaDot, Origen Therapeutics
Featured companies: Change:healthcare, Gemin X Biotechnologies, Ipsogen, the Practice
Featured companies: Ablynx, Cardiosolutions, Carigent Thereapeutics, Elusys, Genome Corp., GlobeImmune, Novazone, Targanta Therapeutics, Waterfront Media
Featured companies: Adnexus Therapeutics, Bristol-Myers Squibb, Cellerix, Elixir Therapeutics, GenomeQuest, Intronn, JapanBridge, JenaValve, VirXsys, Ysios Capital
Featured companies: BioVascular, Carefx, ClinResearch, Healthcare Management Directions, NanoCor, OxyPlus, Revitus, Spotlight Surgical, United BioSource
Featured companies: ProNAi, Rubicor
(UPDATED at 11am PT on Sunday, 8/26/07: See below.)
(UPDATED at 6:30am PT on Friday: See below.)
(UPDATED at 7:40pm PT: See below.)
(UPDATED at 6:40pm PT: See below.)